Brief: Precision Biosciences Announces Investigational New Drug Clearance By Partner TG Therapeutics For Investigation Of Azer-Cel For Multiple Sclerosis
09/08/2024 12:02
Aug 9 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES ANNOUNCES INVESTIGATIONAL NEW DRUG
CLEARANCE BY PARTNER TG THERAPEUTICS FOR INVESTIGATION OF
AZER-CEL FOR MULTIPLE SCLEROSIS
* PRECISION BIOSCIENCES INC - TG THERAPEUTICS ANTICIPATES
COMMENCING A PHASE 1 CLINICAL TRIAL IN 2024.
Source text for Eikon: ID:nBw7MP1Lta
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing